TY - JOUR
T1 - The triple threat to nascent apolipoprotein B
T2 - Evidence for multiple, distinct degradative pathways
AU - Fisher, Edward A.
AU - Pan, Meihui
AU - Chen, Xiaoli
AU - Wu, Xinye
AU - Wang, Hongxing
AU - Jamil, Haris
AU - Sparks, Janet D.
AU - Williams, Kevin Jon
PY - 2001/7/27
Y1 - 2001/7/27
N2 - We previously showed that Ω-3 fatty acids reduce secretion of apolipoprotein B (apoB) from cultured hepatocytes by stimulating post-translational degradation. In this report, we now characterize this process, particularly in regard to the two known processes that degrade newly synthesized apoB, endoplasmic reticulum (ER)-associated degradation and re-uptake from the cell surface. First, we found that Ω-3-induced degradation preferentially reduces the secretion of large, assembled apoB-lipoprotein particles, and apoB polypeptide length is not a determinant. Second, based on several experimental approaches, ER-associated degradation is not involved. Third, re-uptake, the only process known to destroy fully assembled nascent lipoproteins, was clearly active in primary hepatocytes, but Ω-3-induced degradation of apoB continued even when re-uptake was blocked. Cell fractionation showed that Ω-3 fatty acids induced a striking loss of apoB100 from the Golgi, while sparing apoB100 in the ER, indicating a post-ER process. To determine the signaling involved, we used wortmannin, a phosphatidylinositol 3-kinase (PI3K) inhibitor, which blocked most, if not all, of the Ω-3 fatty acid effect. Therefore, nascent apoB is subject to ER-associated degradation, re-uptake, and a third distinct degradative pathway that appears to target lipoproteins after considerable assembly and involves a post-ER compartment and PI3K signaling. Physiologic, pathophysiologic, and pharmacologic regulation of net apoB secretion may involve alterations in any of these three degradative steps.
AB - We previously showed that Ω-3 fatty acids reduce secretion of apolipoprotein B (apoB) from cultured hepatocytes by stimulating post-translational degradation. In this report, we now characterize this process, particularly in regard to the two known processes that degrade newly synthesized apoB, endoplasmic reticulum (ER)-associated degradation and re-uptake from the cell surface. First, we found that Ω-3-induced degradation preferentially reduces the secretion of large, assembled apoB-lipoprotein particles, and apoB polypeptide length is not a determinant. Second, based on several experimental approaches, ER-associated degradation is not involved. Third, re-uptake, the only process known to destroy fully assembled nascent lipoproteins, was clearly active in primary hepatocytes, but Ω-3-induced degradation of apoB continued even when re-uptake was blocked. Cell fractionation showed that Ω-3 fatty acids induced a striking loss of apoB100 from the Golgi, while sparing apoB100 in the ER, indicating a post-ER process. To determine the signaling involved, we used wortmannin, a phosphatidylinositol 3-kinase (PI3K) inhibitor, which blocked most, if not all, of the Ω-3 fatty acid effect. Therefore, nascent apoB is subject to ER-associated degradation, re-uptake, and a third distinct degradative pathway that appears to target lipoproteins after considerable assembly and involves a post-ER compartment and PI3K signaling. Physiologic, pathophysiologic, and pharmacologic regulation of net apoB secretion may involve alterations in any of these three degradative steps.
UR - https://www.scopus.com/pages/publications/0035958917
U2 - 10.1074/jbc.M008885200
DO - 10.1074/jbc.M008885200
M3 - Article
C2 - 11285257
AN - SCOPUS:0035958917
SN - 0021-9258
VL - 276
SP - 27855
EP - 27863
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 30
ER -